Lebrikizumab for Eczema: What the NEJM ADvocate Trials Measured
DOCTOR'S NOTES · ECZEMA EVIDENCE
Adults whose eczema remains moderate or severe despite topical treatment may be offered a discussion about biologics. Lebrikizumab is an injected medicine targeting the interleukin-13 pathway. Its trial results help inform that discussion, but a response percentage cannot select treatment for a particular person.
Read the original comparison
A 2023 New England Journal of Medicine paper reported the 16-week induction results of two randomized, double-blind trials. Participants were adults or adolescents age 12–17 weighing at least 40 kg with moderate-to-severe atopic dermatitis. The primary endpoint combined clear or almost clear skin with at least a two-point improvement on the clinician's global score.
| Trial | Lebrikizumab | Placebo |
|---|---|---|
| ADvocate 1: primary endpoint | 43.1% | 12.7% |
| ADvocate 2: primary endpoint | 33.2% | 10.8% |
The groups included 283 versus 141 participants in the first trial and 281 versus 146 in the second. The trial reported more conjunctivitis among lebrikizumab recipients. These were studies of a specific medicine and regimen, not proof about any cosmetic moisturizer or all patients with eczema.
Why longer-term numbers need context
A separate 52-week report studied maintenance after the induction period. People who met response criteria were randomized again. A maintenance percentage among responders is therefore not the percentage of everyone who started treatment who will have the same outcome at one year. Check who is in the denominator before comparing headlines.
Discuss eligibility and safety
The U.S. EBGLYSS label includes eligible adults and patients age 12 and older weighing at least 40 kg when topical prescriptions do not adequately control the disease or are inadvisable. It discusses hypersensitivity, eye symptoms, helminth infections and vaccine precautions. Tell the prescriber about your medical history, other treatment and any new eye discomfort. Seek urgent help for severe allergic symptoms.
Ask how response will be measured, what follow-up is needed, how to store the medicine, and what training is provided for injections. Include practical priorities such as sleep, painful hand use or missed work alongside the clinical skin score. Do not change or combine prescriptions on the basis of a trial table.
Our dupilumab evidence guide describes another biologic. For the difference between a severity improvement and being clear, see EASI-75 explained.
Use the same endpoint when comparing results
In ADvocate 1 the difference on the primary endpoint was 30.4 percentage points; in ADvocate 2 it was 22.4 points. These are absolute differences for the trial's defined 16-week outcome. They are not permanent-clearance rates, and comparing them directly with a percentage from an unrelated drug trial may be misleading if the populations, accompanying therapy or outcome definitions differ.
It can help to keep two questions separate: “How many people met this strict skin endpoint?” and “What other improvements did people experience?” Neither question alone describes the whole experience of living with eczema.
Prepare for a shared treatment decision
Bring your prior treatment history and the practical constraints that matter to you. Ask how the team will distinguish partial response from inadequate control, what eye symptoms should be reported and which medicines are intended to continue. If the plan includes maintenance treatment, clarify how that decision is based on your response rather than assuming a trial responder analysis predicts your outcome. The goal is a transparent individual plan, not a contest between isolated percentages.
Follow the related evidence
The Level Up direct comparison illustrates a different trial design. Our nemolizumab ARCADIA guide discusses another biologic and the role of accompanying topical care.
Prepared by the Dr. Arsy editorial team. Sources checked November 8, 2026. Educational information supports a discussion with a qualified clinician; it does not diagnose or prescribe for an individual. The AI-created product image is an editorial illustration, not a patient photograph or a clinical result.